Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
421.39
-1.24 (-0.29%)
At close: Oct 24, 2025, 4:00 PM EDT
421.00
-0.39 (-0.09%)
After-hours: Oct 24, 2025, 7:16 PM EDT
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.96B in the quarter ending June 30, 2025, with 12.06% growth. This brings the company's revenue in the last twelve months to $11.42B, up 10.46% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.42B
Revenue Growth
+10.46%
P/S Ratio
9.49
Revenue / Employee
$1,871,934
Employees
6,100
Market Cap
108.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
| Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
| Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
| Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
| Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
VRTX News
- 2 days ago - Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference - Business Wire
- 8 days ago - Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week - Business Wire
- 18 days ago - Vertex to Announce Third Quarter 2025 Financial Results on November 3rd - Business Wire
- 4 weeks ago - Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership - Seeking Alpha
- 4 weeks ago - Vertex Announces Key Advancements Across Kidney Portfolio - Business Wire
- 4 weeks ago - Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain - Business Wire
- 4 weeks ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bank of America Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 5 weeks ago - Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy - Business Wire